Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma

NCT02955771 is registered in ClinicalTrials.gov with Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02955771
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02955771 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Terminated
Start date
May 17, 2017
Completion date
December 26, 2018
Enrollment
7 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hilar cholangiocarcinoma